Neuroendocrine Prostate Cancer Market Set to Grow Through 2034

DelveInsight's "Neuroendocrine Prostate Cancer (NEPC) - Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of NEPC epidemiology, market, and clinical development, along with historical and forecasted epidemiology and market data across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the neuroendocrine prostate cancer market outlook, treatment uptake, and competitive landscape, click here: https://www.delveinsight.com/report-store/neuroendocrine-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Some of the Key Facts of the Neuroendocrine Prostate Cancer Market Report
• In 2024, the US accounted for the highest prevalent cases of prostate cancer among the 7MM, at approximately 3,751,850 cases.
• Prostate cancer is most frequently diagnosed in men aged 65-74, with a median diagnosis age of 66, and as life expectancy rises, more men are entering high-risk age groups.
• Approximately 60% of prostate cancer patients are diagnosed at localized or locally advanced stages, while around 33% go on to develop biochemical recurrence.
• Approximately 1% of prostate cancer patients present with pure neuroendocrine histology at diagnosis, while 15-20% of advanced-stage cases may develop neuroendocrine features over time as a resistance mechanism to hormonal therapy.
• Currently, there is no FDA-approved therapy specifically indicated for the treatment of NEPC, leaving platinum-based chemotherapy regimens borrowed from small cell lung cancer as the primary treatment approach.
• In February 2024, BioXcel Therapeutics received Fast Track Designation from the FDA for BXCL701 in combination with a checkpoint inhibitor for small cell neuroendocrine carcinoma (SCNC) progressing on chemotherapy.
• As per BioXcel Therapeutics' corporate presentation published in April 2025, the company anticipates an FDA meeting for BXCL701 in SCNC.
• In August and December 2024, Phanes Therapeutics' PT217 received Orphan Drug Designation and Fast Track Designation, respectively, for neuroendocrine carcinoma and metastatic de novo or treatment-emergent NEPC.

Key Neuroendocrine Prostate Cancer Companies
• OnkosXcel Therapeutics (a Subsidiary of BioXcel Therapeutics)
• Phanes Therapeutics
• Amgen
• Novartis
• Fusion Pharma
• Others

Key Neuroendocrine Prostate Cancer Therapies
• BXCL701
• Peluntamig (PT217)
• IMDELLTRA/IMDYLLTRA (tarlatamab/AMG 757)
• PLUVICTO (lutetium Lu 177 vipivotide tetraxetan)
• FPI-2059
• Others

The neuroendocrine prostate cancer market is expected to gain momentum due to rising recognition of treatment-emergent NEPC as a resistance mechanism following androgen deprivation and androgen receptor pathway inhibitor therapy, growing use of routine repeat biopsy to detect transformation, and an increasingly active pipeline spanning DPP-directed immune activators, DLL3-targeted bispecific antibodies and T-cell engagers, and PSMA-targeted radioligand therapy. The advancement of BXCL701, Peluntamig, and other emerging candidates is expected to reshape competitive dynamics over the forecast period.

Neuroendocrine Prostate Cancer Overview
Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or emerge in patients previously treated with hormonal therapies for prostate adenocarcinoma, characterized by:
• De novo NEPC, occurring without prior diagnosis or treatment for prostate adenocarcinoma, versus treatment-emergent NEPC (t-NEPC), which develops through transformation of regular adenocarcinoma after androgen deprivation therapy.
• A dismal prognosis, with NEPC patients facing a 5-year life expectancy and low survival rates regardless of disease origin.
• Diagnosis based on metastatic tumor biopsy confirming tumor morphology, with NCCN guidelines recommending biopsy consideration in patients with aggressive disease, atypical spread, or progression with low or non-rising PSA levels.
• Frequent underdiagnosis in ARPI-related mCRPC due to a lack of validated biomarkers, making routine repeat biopsy essential to detect t-NEPC transitions.

Get a free sample for the Neuroendocrine Prostate Cancer Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/neuroendocrine-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Neuroendocrine Prostate Cancer Market Segmentation
The neuroendocrine prostate cancer market report proffers detailed analysis for the study period 2020-2034 segmented into:
By Region/Geography
• North America (US)
• Europe (Germany, France, Italy, Spain, and the UK)
• Asia-Pacific (Japan)

By Drugs/Therapies
By Epidemiology Segmentation
• Total incident cases of prostate cancer
• Total incident cases of NEPC
• Type-specific cases of NEPC
• Treated cases of NEPC

Download the report to understand which factors are driving neuroendocrine prostate cancer market trends: https://www.delveinsight.com/report-store/neuroendocrine-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Neuroendocrine Prostate Cancer Treatment Landscape
Management of neuroendocrine prostate cancer centers on controlling an aggressive, treatment-refractory disease with limited standard options:
• Platinum-based chemotherapy, typically carboplatin or cisplatin combined with etoposide or a taxane, remains the preferred regimen for pure small cell carcinoma or t-NEPC, drawing on data from small cell lung cancer, as no FDA-approved therapy currently exists for NEPC specifically.
• BXCL701 (OnkosXcel Therapeutics, a subsidiary of BioXcel Therapeutics) is an oral, investigational innate immune activator targeting dipeptidyl peptidases, which demonstrated a 25% composite response rate in a Phase IIa trial in SCNC-phenotype mCRPC and holds FDA Fast Track Designation.
• Peluntamig (PT217) (Phanes Therapeutics) is a first-in-class bispecific antibody targeting DLL3 and CD47, currently being evaluated in the Phase I/II SKYBRIDGE trial as monotherapy or combined with TECENTRIQ (atezolizumab) in DLL3-expressing cancers including NEPC, and holds both Orphan Drug and Fast Track Designations.
• IMDELLTRA/IMDYLLTRA (tarlatamab/AMG 757) (Amgen) is a DLL3xCD3 bispecific T-cell engager (BiTE) molecule in Phase I development for NEPC.
• PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) (Novartis) is a PSMA-targeted radioligand therapy in Phase I development for metastatic NEPC.
• FPI-2059 (Fusion Pharma) is a small molecule targeting neurotensin receptor 1 (NTSR1) in Phase I development for neuroendocrine differentiated prostate cancer.

Discover more about therapies set to grab major neuroendocrine prostate cancer market share: https://www.delveinsight.com/report-store/neuroendocrine-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Neuroendocrine Prostate Cancer Market Strengths
• A robust and mechanistically diverse pipeline spanning DPP-directed small molecules, DLL3-targeted bispecific antibodies and BiTE molecules, and PSMA-targeted radioligand therapy signals growing pipeline maturity.
• Multiple regulatory milestones, including Fast Track and Orphan Drug Designations for BXCL701 and PT217, reflect accelerated development pathways and growing regulatory recognition of NEPC as a distinct clinical entity.
• Increasing clinical awareness of treatment-emergent NEPC as an ARPI resistance mechanism is driving greater diagnostic vigilance and routine repeat biopsy protocols.

Neuroendocrine Prostate Cancer Market Opportunities
• The complete absence of an FDA-approved, NEPC-specific therapy represents substantial white space for first-to-market approval among current pipeline candidates.
• The lack of validated biomarkers for early detection of NEPC transformation represents a significant unmet need and an opportunity for companion diagnostic development alongside emerging therapies.

Scope of the Neuroendocrine Prostate Cancer Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Coverage: The US; Germany, France, Italy, and Spain (EU4); the UK; Japan
• Key Companies: OnkosXcel Therapeutics (a Subsidiary of BioXcel Therapeutics), Phanes Therapeutics, Amgen, Novartis, Fusion Pharma, and others
• Key Therapies: BXCL701, Peluntamig (PT217), IMDELLTRA/IMDYLLTRA (tarlatamab/AMG 757), PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), FPI-2059, and others
• Market CAGR (Forecast Period): Insights available in the full report (2025-2034)
• Analysis Includes: KOL views, SWOT analysis, conjoint analysis, reimbursement, unmet needs, market drivers and barriers, epidemiology patient burden

To know more about neuroendocrine prostate cancer companies working in the market, visit: https://www.delveinsight.com/report-store/neuroendocrine-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Neuroendocrine Prostate Cancer Market Report Introduction
2. Executive Summary for Neuroendocrine Prostate Cancer
3. SWOT Analysis of Neuroendocrine Prostate Cancer
4. Neuroendocrine Prostate Cancer Market Overview at a Glance
5. Neuroendocrine Prostate Cancer Disease Background and Overview
6. Neuroendocrine Prostate Cancer Market Segmentation and Analysis
7. Regional Analysis of the Neuroendocrine Prostate Cancer Market
8. Country-Specific Neuroendocrine Prostate Cancer Market Analysis
9. Competitive Landscape and Key Company Profiles
10. Neuroendocrine Prostate Cancer Unmet Needs
11. Neuroendocrine Prostate Cancer Emerging Therapies and Pipeline
12. Neuroendocrine Prostate Cancer Market Outlook
13. Neuroendocrine Prostate Cancer Market Access and Reimbursement
14. Neuroendocrine Prostate Cancer Market Drivers
15. Neuroendocrine Prostate Cancer Market Barriers
16. Neuroendocrine Prostate Cancer Recent Developments
17. Neuroendocrine Prostate Cancer Appendix
18. Neuroendocrine Prostate Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma and diagnostics companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.